These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

760 related articles for article (PubMed ID: 29541282)

  • 21. Cost-effectiveness of a novel hybrid closed-loop system compared with continuous subcutaneous insulin infusion in people with type 1 diabetes in the UK.
    Roze S; Buompensiere MI; Ozdemir Z; de Portu S; Cohen O
    J Med Econ; 2021; 24(1):883-890. PubMed ID: 34098834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial.
    Wan W; Skandari MR; Minc A; Nathan AG; Winn A; Zarei P; O'Grady M; Huang ES
    Diabetes Care; 2018 Jun; 41(6):1227-1234. PubMed ID: 29650803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring system in people with type 1 diabetes in Australia.
    Isitt JJ; Roze S; Tilden D; Arora N; Palmer AJ; Jones T; Rentoul D; Lynch P
    Diabet Med; 2022 Jul; 39(7):e14831. PubMed ID: 35298036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.
    Jendle J; Pöhlmann J; de Portu S; Smith-Palmer J; Roze S
    Diabetes Technol Ther; 2019 Mar; 21(3):110-118. PubMed ID: 30785311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medical resource use, disturbance of daily life and burden of hypoglycemia in insulin-treated patients with diabetes: results from a European online survey.
    Willis WD; Diago-Cabezudo JI; Madec-Hily A; Aslam A
    Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):123-30. PubMed ID: 23402452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A clinical and economic evaluation of Control of Hyperglycaemia in Paediatric intensive care (CHiP): a randomised controlled trial.
    Macrae D; Grieve R; Allen E; Sadique Z; Betts H; Morris K; Pappachan VJ; Parslow R; Tasker RC; Baines P; Broadhead M; Duthie ML; Fortune PM; Inwald D; McMaster P; Peters MJ; Schindler M; Guerriero C; Piercy D; Slavik Z; Snowdon C; Van Dyck L; Elbourne D
    Health Technol Assess; 2014 Apr; 18(26):1-210. PubMed ID: 24780450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The 30-year cost-effectiveness of alternative strategies to achieve excellent glycemic control in type 1 diabetes: An economic simulation informed by the results of the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC).
    Herman WH; Braffett BH; Kuo S; Lee JM; Brandle M; Jacobson AM; Prosser LA; Lachin JM
    J Diabetes Complications; 2018 Oct; 32(10):934-939. PubMed ID: 30064713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of predicted low suspend pump treatment on improving glycaemic control and quality of sleep in children with type 1 diabetes and their caregivers: the QUEST randomized crossover study.
    Schierloh U; Aguayo GA; Fichelle M; De Melo Dias C; Celebic A; Vaillant M; Barnard K; Cohen O; de Beaufort C
    Trials; 2018 Dec; 19(1):665. PubMed ID: 30509293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2022; 22(3):1-155. PubMed ID: 36158868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
    Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
    J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of G5 Mobile continuous glucose monitoring device compared to self-monitoring of blood glucose alone for people with type 1 diabetes from the Canadian societal perspective.
    Chaugule S; Graham C
    J Med Econ; 2017 Nov; 20(11):1128-1135. PubMed ID: 28745578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment satisfaction and quality of life for an integrated continuous glucose monitoring/insulin pump system compared to self-monitoring plus an insulin pump.
    Rubin RR; Peyrot M
    J Diabetes Sci Technol; 2009 Nov; 3(6):1402-10. PubMed ID: 20144395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Level 2 Polysomnography for the Diagnosis of Sleep Disorders: A Health Technology Assessment.
    Ontario Health
    Ont Health Technol Assess Ser; 2024; 24(7):1-157. PubMed ID: 39372311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System Compared to Standard Management of Type 1 Diabetes in a Singapore Setting.
    Gardner D; Lakkad M; Qiu Z; Inoue Y; Rama Chandran S; Wherry K
    Diabetes Technol Ther; 2024 May; 26(5):324-334. PubMed ID: 38215206
    [No Abstract]   [Full Text] [Related]  

  • 35. Personalizing the Use of a Intermittently Scanned Continuous Glucose Monitoring Device in Individuals With Type 1 Diabetes: A Cost-Effectiveness Perspective in the Netherlands (FLARE-NL 9).
    Emamipour S; van Dijk PR; Bilo HJG; Edens MA; van der Galiën O; Postma MJ; Feenstra TL; van Boven JFM
    J Diabetes Sci Technol; 2024 Jan; 18(1):135-142. PubMed ID: 35815617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carrier Screening Programs for Cystic Fibrosis, Fragile X Syndrome, Hemoglobinopathies and Thalassemia, and Spinal Muscular Atrophy: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2023; 23(4):1-398. PubMed ID: 37637488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-time continuous glucose monitoring vs. self-monitoring of blood glucose: cost-utility in South Korean type 2 diabetes patients on intensive insulin.
    Kim JY; Ilham S; Alshannaq H; Pollock RF; Ahmed W; Norman GJ; Jin SM; Kim JH
    J Med Econ; 2024; 27(1):1245-1252. PubMed ID: 39275990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glycemic Variability and Hypoglycemic Excursions With Continuous Glucose Monitoring Compared to Intermittently Scanned Continuous Glucose Monitoring in Adults With Highest Risk Type 1 Diabetes.
    Avari P; Moscardo V; Jugnee N; Oliver N; Reddy M
    J Diabetes Sci Technol; 2020 May; 14(3):567-574. PubMed ID: 31375042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term Cost-Effectiveness of Dexcom G6 Real-time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Patients With Type 1 Diabetes in the U.K.
    Roze S; Isitt J; Smith-Palmer J; Javanbakht M; Lynch P
    Diabetes Care; 2020 Oct; 43(10):2411-2417. PubMed ID: 32647050
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.